Medical Technology News

Psoriasis Treatment Market Size, Share, Production, Growth, Trends, and Forecast 2019-2026

Press release   •   Sep 14, 2019 12:56 EDT

The global psoriasis treatment market is estimate this market to rise at a CAGR of 7.4% between 2019 and 2026 and reach US$13.3 bn by 2026.

This report on the Psoriasis Treatment market analyzes the current and future scenario of the global market. Approval of new biologics, increase in access for the treatment in developing market, increase in the number of psoriasis patients, are boosting the growth of the global Psoriasis Treatment market. Increase in the incidence of Psoriasis and skin disorders, and novel pipeline drugs are some of the factors expected to drive the growth of global Psoriasis Treatment market during the forecast period.

The Psoriasis Treatment market report comprises an elaborate executive summary, which includes market snapshot that provides information about various segments. It also provides information and data analysis of the global market with respect to the segments based on products, distribution channel, therapy type and geography. A detailed qualitative analysis of drivers and restraints, and opportunities has been provided in the market overview section.

Get Sample Copy of Report@ https://www.visionresearchreports.com/report/sample/24883

Additionally, the section comprises Porter’s Five Forces Analysis to help understand the competitive landscape in the market. This section also provides market attractiveness analysis in terms of geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global Psoriasis Treatment market.

Segmentation

In this report, the market segments have been analyzed based on availability of approved products, cost-effectiveness, and preference for technological systems by physicians and patients. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2019 to 2026, considering 2018 as the base year.

Based on product type, the market has been segmented into TNF Inhibitors, Vitamin D analogues or its combination, Interleukin Blockers and Others. Interleukin blockers segment is likely to be the most attractive segment in the near future due to its increasing use and its ability to act selectively by targeting the proteins. The segment is expected to grow at a highest CAGR rate during forecast period.

Based on Therapy type, the global Psoriasis Treatment market has been segmented into Topical Therapeutic Drugs, Systemic Therapeutic Drugs, Combinations of therapies & others. The market segments have been extensively analyzed based on increase in demand for the therapies, availability of the drug products, and cost of therapy and severity of the disease.

Different types of distribution channels are responsible for making the psoriasis treatment available in the market. The distribution channels are Hospital pharmacy, Retail pharmacy and the online sales. Under the distribution channel segment, hospital pharmacy plays a major role followed by retail pharmacy and online sales.

Geographically, the global Psoriasis Treatment market has been categorized into five major regions and the key countries in the respective region: North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, Japan, China, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, Saudi Arabia, and Rest of Middle East & Africa).

Request to Buy this Premium Report From Here@ https://www.visionresearchreports.com/report/cart/24883

Companies Mentioned in the Report

The report also profiles major players in the global Psoriasis Treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, SWOT analysis, and recent developments. Major players profiled in this report include Amgen Inc., Eli Lilly and Company, Novartis AG, Merck & Co., Inc., Johnson & Johnson, Pfizer, Inc., AstraZeneca, AbbVie Inc., LEO Pharma A/S and Biogen.

The Global Psoriasis Treatment Market has been segmented as given below:

By Product

  • TNF Inhibitors
  • Vitamin D Analogues or Combinations
  • Interleukin Blockers
  • Others

By Therapy

  • Topical Therapeutic Drugs
  • Systemic Therapeutic Drugs
  • Combinations
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Sales
  • Others

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Rest of Middle East & Africa

Request to Buy this Premium Report From Here@ https://www.visionresearchreports.com/report/cart/24883

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights

2. Assumptions and Research Methodology
2.1. Assumptions
2.2. Research Methodology

3. Executive Summary
3.1. Global Psoriasis Treatment Market Snapshot
3.2. Market Share Analysis by Region, 2018
3.3. Global Psoriasis Treatment Market : Opportunity Map

4. Market Overview
4.1. Product Overview
4.2. Global Psoriasis Treatment Market : Key Industry Events
4.3. Global Psoriasis Treatment Market Size (US$ Mn) Forecast, 2016–2026
4.4. Psoriasis Treatment Market Outlook
4.5. Global Psoriasis Treatment Supply Demand Scenario
4.6. Porter’s Analysis

5. Market Dynamics
5.1. Drivers
5.1.1. Approval of new biologics
5.1.2. Increase in access for treatment in developing markets
5.1.3. Novel Pipeline Drugs
5.1.4. Increase in the number of psoriasis patients
5.2. Restrains
5.2.1. Loss of response to current therapies
5.2.2. Premium-priced biologics
5.3. Opportunities
5.3.1. Newer modalities and availability of predictive biomarkers, offer opportunity of personalized treatment for psoriasis
5.3.2. Specialty biologics set to lose their exclusivity status
5.4. Key Trends
5.4.1. Increasing cost of psoriasis biologics
5.4.2. The number of physicians that practice independently has been declining

6. Psoriasis Treatment Market Analysis, by Product Type
6.1. Key Findings
6.2. Introduction
6.3. Global Psoriasis Treatment Market Value Share Analysis, by Product Type
6.4. Psoriasis Treatment Market Analysis, by Product Type
6.4.1. TNF Inhibitors
6.4.2. Vitamin D Analogues or Combinations
6.4.3. Interleukin Blockers
6.4.4. Others
6.5. Psoriasis Treatment Market Attractiveness Analysis, by Product Type
6.6. Key Trends

7. Psoriasis Treatment Market Analysis, by Therapy
7.1. Key Findings
7.2. Introduction
7.3. Global Psoriasis Treatment Market Value Share Analysis, by Therapy
7.4. Psoriasis Treatment Market Analysis, by Therapy
7.4.1. Topical Therapeutic Drugs
7.4.2. Systemic Therapeutic Drugs
7.4.3. Combinations & Others
7.5. Psoriasis Treatment Market Attractiveness Analysis, by Therapy
7.6. Key Trends

8. Psoriasis Treatment Market Analysis, by Distribution Channel
8.1. Key Findings
8.2. Introduction
8.3. Global Psoriasis Treatment Market Value Share Analysis, by Distribution Channel
8.4. Psoriasis Treatment Market Analysis, by Distribution Channel
8.4.1. Hospital Pharmacy
8.4.2. Retail Pharmacy
8.4.3. Online Sales
8.5. Psoriasis Treatment Market Attractiveness Analysis, by Distribution Channel
8.6. Key Trends

9. Psoriasis Treatment Market Analysis, by Region
9.1. Global Psoriasis Treatment Market Snapshot, by Country
9.2. Global Psoriasis Treatment Market Value Share Analysis, by Region
9.3. Psoriasis Treatment Market Forecast, by Region
9.4. Psoriasis Treatment Market Attractiveness Analysis, by Region

10. North America Psoriasis Treatment Market Analysis
10.1. Key Findings
10.2. North America Psoriasis Treatment Market Overview
10.3. North America Market Value Share Analysis, by Product
10.4. North America Market Forecast, by Product
10.4.1. TNF Inhibitors
10.4.2. Vitamin D Analogues or Combinations
10.4.3. Interleukin Blockers
10.4.4. Others
10.5. North America Market Value Share Analysis, by Therapy
10.6. North America Market Forecast, by Therapy
10.6.1. Topical Therapeutic Drugs
10.6.2. Systemic Therapeutic Drugs
10.6.3. Combinations & Others
10.7. North America Psoriasis Treatment Market Value Share Analysis, by Distribution Channel
10.8. North America Market Forecast, by Distribution Channel
10.8.1. Hospital Pharmacy
10.8.2. Retail Pharmacy
10.8.3. Online Sales
10.9. Market Analysis, by Country
10.10. Market Value Share Analysis, by Country
10.11. Market Size (US$ Mn) Forecast, by Country, 2019–2026
10.11.1. U.S.
10.11.2. Canada
10.12. Market Attractiveness Analysis
10.12.1. By Product
10.12.2. By Therapy
10.12.3. By Distribution Channel
10.12.4. By Country
10.13. Market Trends

11. Europe Psoriasis Treatment Market Analysis
11.1. Key Findings
11.2. Europe Psoriasis Treatment Market Overview
11.3. Europe Market Value Share Analysis, by Product
11.4. Europe Market Forecast, by Product
11.4.1. TNF Inhibitors
11.4.2. Vitamin D Analogues or Combinations
11.4.3. Interleukin Blockers
11.4.4. Others
11.5. Europe Market Value Share Analysis, by Therapy
11.6. Europe Market Forecast, by Therapy
11.6.1. Topical Therapeutic Drugs
11.6.2. Systemic Therapeutic Drugs
11.6.3. Combinations & Others
11.7. Europe Psoriasis Treatment Market Value Share Analysis, by Distribution Channel
11.8. Europe Market Forecast, by Distribution Channel
11.8.1. Hospital Pharmacy
11.8.2. Retail Pharmacy
11.8.3. Online Sales
11.9. Market Analysis, by Country
11.10. Market Value Share Analysis, by Country
11.11. Market Size (US$ Mn) Forecast, by Country, 2019–2026
11.11.1. Germany
11.11.2. U.K.
11.11.3. Spain
11.11.4. Italy
11.11.5. France
11.11.6. Rest of Europe
11.12. Market Attractiveness Analysis
11.12.1. By Product
11.12.2. By Therapy
11.12.3. By Distribution Channel
11.12.4. By Country
11.13. Market Trends

12. Asia Pacific Psoriasis Treatment Market Analysis
12.1. Key Findings
12.2. Asia Pacific Psoriasis Treatment Market Overview
12.3. Asia Pacific Market Value Share Analysis, by Product
12.4. Asia Pacific Market Forecast, by Product
12.4.1. TNF Inhibitors
12.4.2. Vitamin D Analogues or Combinations
12.4.3. Interleukin Blockers
12.4.4. Others
12.5. Asia Pacific Market Value Share Analysis, by Therapy
12.6. Asia Pacific Market Forecast, by Therapy
12.6.1. Topical Therapeutic Drugs
12.6.2. Systemic Therapeutic Drugs
12.6.3. Combinations & Others
12.7. Asia Pacific Psoriasis Treatment Market Value Share Analysis, by Distribution Channel
12.8. Asia Pacific Market Forecast, by Distribution Channel
12.8.1. Hospital Pharmacy
12.8.2. Retail Pharmacy
12.8.3. Online Sales
12.9. Market Analysis, by Country
12.10. Market Value Share Analysis, by Country
12.11. Market Size (US$ Mn) Forecast, by Country, 2019–2026
12.11.1. Japan
12.11.2. China
12.11.3. Australia & New Zealand
12.11.4. India
12.11.5. Rest of Asia Pacific
12.12. Market Attractiveness Analysis
12.12.1. By Product
12.12.2. By Therapy
12.12.3. By Distribution Channel
12.12.4. By Country
12.13. Market Trends

13. Latin America Psoriasis Treatment Market Analysis
13.1. Key Findings
13.2. Latin America Psoriasis Treatment Market Overview
13.3. Latin America Market Value Share Analysis, by Product
13.4. Latin America Market Forecast, by Product
13.4.1. TNF Inhibitors
13.4.2. Vitamin D Analogues or Combinations
13.4.3. Interleukin Blockers
13.4.4. Others
13.5. Latin America Market Value Share Analysis, by Therapy
13.6. Latin America Market Forecast, by Therapy
13.6.1. Topical Therapeutic Drugs
13.6.2. Systemic Therapeutic Drugs
13.6.3. Combinations & Others
13.7. Latin America Psoriasis Treatment Market Value Share Analysis, by Distribution Channel
13.8. Latin America Market Forecast, by Distribution Channel
13.8.1. Hospital Pharmacy
13.8.2. Retail Pharmacy
13.8.3. Online Sales
13.9. Market Analysis, by Country
13.10. Market Value Share Analysis, by Country
13.11. Market Size (US$ Mn) Forecast, by Country, 2019–2026
13.11.1. Brazil
13.11.2. Mexico
13.11.3. Rest of Latin America
13.12. Market Attractiveness Analysis
13.12.1. By Product
13.12.2. By Therapy
13.12.3. By Distribution Channel
13.12.4. By Country
13.13. Market Trends

14. Middle East & Africa Psoriasis Treatment Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Psoriasis Treatment Market Overview
14.3. Middle East & Africa Market Value Share Analysis, by Product
14.4. Middle East & Africa Market Forecast, by Product
14.4.1. TNF Inhibitors
14.4.2. Vitamin D Analogues or Combinations
14.4.3. Interleukin Blockers
14.4.4. Others
14.5. Middle East & Africa Market Value Share Analysis, by Therapy
14.6. Middle East & Africa Market Forecast, by Therapy
14.6.1. Topical Therapeutic Drugs
14.6.2. Systemic Therapeutic Drugs
14.6.3. Combinations & Others
14.7. Middle East & Africa Psoriasis Treatment Market Value Share Analysis, by Distribution Channel
14.8. Middle East & Africa Market Forecast, by Distribution Channel
14.8.1. Hospital Pharmacy
14.8.2. Retail Pharmacy
14.8.3. Online Sales
14.9. Market Analysis, by Country
14.10. Market Value Share Analysis, by Country
14.11. Market Size (US$ Mn) Forecast, by Country, 2019–2026
14.11.1. South Africa
14.11.2. Saudi Arabia
14.11.3. Rest of Middle East & Africa
14.12. Market Attractiveness Analysis
14.12.1. By Product
14.12.2. By Therapy
14.12.3. By Distribution Channel
14.12.4. By Country
14.13. Market Trends

15. Company Profiles
15.1. Psoriasis Treatment Market Share Analysis, by Company (2018)
15.2. Competition Matrix
15.3. Company Profiles
15.3.1. Amgen, Inc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Eli Lilly & Company
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Novartis AG
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Merck & Co., Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Johnson & Johnson
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Pfizer, Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. AstraZeneca
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. AbbVie, Inc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. LEO Pharma A/S
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. Biogen
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Financial Overview
15.3.10.3. Product Portfolio
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview

Request to Buy this Premium Report From Here@ https://www.visionresearchreports.com/report/cart/24883